Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PPCB
PROPANC BIOPHARMA, INC.
NASDAQ
$1.08
▼ DOWN 1.82% (-0.02)

KEY STATISTICS

Market Cap$2.46 M
52w High$86.14
52w Low$0.95
Dividend Yield—
Frequency—
P/E-0.13
Volume25.22K
Shares Out.2.28M

COMPANY

LEADERSHIP

James Nathanielsz
CHIEF EXECUTIVE
James Nathanielsz

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 12, 2012
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
2

SPLIT RECORD

DATETYPERATIO
2026-05-18Reverse1:25
2025-01-29Reverse1:60000
2023-05-23Reverse1:1000
2020-11-19Reverse1:1000
2019-06-24Reverse1:500
2017-04-20Reverse1:250
2017-04-07Reverse1:250

PRICE

$1.08 ▼ DOWN 1.82% (−$0.02)
OVERLAYS
$1.07$1.10$1.129:34 AM10:38 AM11:42 AM12:46 PM1:51 PM2:55 PM3:59 PM1.08

About Propanc Biopharma, Inc.

https://www.propanc.com ↗

Propanc Biopharma, Inc. is an Australian biopharmaceutical company developing cancer treatments, including its preclinical PRP formulation, with collaborations like the POP1 drug discovery program.

INDUSTRY

Biotechnology

A PRODUCT PROPANC BIOPHARMA, INC. IS KNOWN FOR

PRP
PRP

Propanc Biopharma's lead proenzyme therapy, an intravenous formulation targeting cancer stem cells in metastatic solid tumors, is in preclinical development and preparing for a Phase 1b trial in advanced cancer patients.

COMPETITORS

COMPETITOR
IBRX COMPARE
IMRX COMPARE
NVCR COMPARE
ONCY COMPARE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score2